Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
6.55    0.00 (0.00%)
Bid:
6.20
Ask:
6.90
Spread: 0.70 (11.29%)
Market Cap: £70.42m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Net Asset Value(s)

15 Oct 2020 07:00

RNS Number : 1266C
Agronomics Limited
15 October 2020
 

15 October 2020

Agronomics Limited

(the "Company")

Net Asset Value calculation to 30 September 2020

Agronomics Limited (AIM:ANIC), a leading listed investor in cellular agriculture with a focus on cultivated meat and alternative proteins, announces that its Net Asset Valuation ("NAV") calculation as at closing on 30 September 2020 was 5.62 pence per share, including un-invested cash of £0.3 million. The portfolio is valued under IFRS at bid price. The share price of 5 pence at the 30 September 2020 close represents a discount of 13.85% to the NAV. Net Assets stand at £18.6 million, including investments of £20.4 million. This quarter's NAV per share represents a decrease of 1% from the previous quarters NAV of 5.68 pence per share, which included un-invested cash of £2.8 million. No management fee is due to Shellbay Investments Limited.

Following the draw-down of the Galloway Limited loan facility in September 2020, the Company completed two investments during the quarter.

 

The Company acquired 1,127 Series A Preferred Shares in Solar Foods Oy, for a consideration of EUR 3 million. Solar Foods develops a sustainable protein called Solein®, a microorganism that grows utilising airborne carbon dioxide and hydrogen via the electrolysis of water.

 

As part of a US$ 55 million financing lead by Blue Horizon Ventures, the Company invested an initial US$ 2.05 million in Mosa Meats B.V.. In total, Agronomics has committed to investment of US$ 4.1 million into Mosa Meats B.V with the financing being split into two tranches. Mosa Meat is a cultivated meat company based in the Netherlands, whose founding scientist, Professor Mark Post, showcased the world's first cultivated burger in 2013. Mosa Meat is focused initially on cultivated beef products, intending to have products approved in the EU in 2023.

 

Towards the end of September 2020, Shiok Meats Pte. Ltd completed a Series A financing. Following this, the convertible loan note investment, plus accrued interest to date, converted into Series A Preferred Shares at a 20% discount. This resulted in a 28% uplift to the carrying value of our investment in Shiok Meats.

 

Since the start of January 2020, the outbreak of coronavirus, which is a rapidly evolving situation, has adversely impacted global commercial activities. The rapid development and fluidity of this situation precludes any prediction as its ultimate impact, which may have a continued adverse impact on economic and market conditions and trigger a period of global economic slowdown. The Directors do not believe there is any direct financial impact on the Company, but we continue to monitor any impact on both the Company and its investee holdings.

Unaudited to

30 September 2020 £

Fixed Assets

Investments

20,430,818

Current Assets

Uninvested Cash

301,551

Sundry Debtors

32,450

Current Liabilities

Trade and Other Creditors

(218,278)

Loan Advances

(1,900,000)

18,646,541

Capital and Reserves

Share Capital

23

Share Premium

19,578,859

Retained Earnings

(932,341)

18,646,541

Shares in Issue

331,616,661

Net Asset Value per share

5.62 pence

 

Portfolio Details

Investments as at 30 September 2020

Value (£)

% of Total Portfolio

Quoted holdings

447,765

2.2%

Unquoted holdings

19,983,053

97.8%

Total

20,430,818

100%

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain. 

For further information, please contact:

Agronomics Limited

Beaumont Cornish Limited

Cenkos Securities Plc

Peterhouse Capital Limited

Britton Financial PR

The Company

Nomad

Joint Broker

Joint Broker

Investor Relations

Denham Eke

+44 (0) 1624 639396

Roland Cornish/James Biddle

+44 (0) 207 628 3396

Giles Balleny

Max Gould

Michael Johnson (Broking)

+44 (0) 20 7937 8900

Lucy Williams

+44 (0) 207 469 0936

 

Tim Blackstone

+44 (0)7957 140416

 

 

About Agronomics

Agronomics is a leading listed investor in cellular agriculture with a focus on cultivated meat and alternative proteins.

 

The Company invests in technologies that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population.

 

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVBLBDGISBDGGS
Date   Source Headline
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.